Axsome Therapeutics Inc. ((AXSM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Axsome Therapeutics Inc. is conducting an open-label Phase 3 study titled ‘An Open-Label Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults with Binge Eating Disorder’. The study aims to evaluate the safety and efficacy of solriamfetol for treating binge eating disorder (BED) in adults, highlighting its potential significance in addressing this condition.
The intervention being tested is solriamfetol, a drug administered in doses of 75mg, 150mg, or 300mg, taken once daily. It is intended to manage symptoms of binge eating disorder.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. The open-label design allows all participants to receive the active treatment, providing insights into its long-term safety and efficacy.
The study commenced on March 14, 2025, with the same date marking its last update. While the primary completion and estimated completion dates are not specified, these milestones are crucial for tracking progress and anticipating results.
The study’s progress could influence Axsome Therapeutics’ stock performance by enhancing investor confidence in its pipeline. Success in this study may position Axsome favorably against competitors in the BED treatment market, potentially impacting industry dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.